Cellistic

BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

BrightPath Bio and Cellistic Announce Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell

Tokyo, Japan and Mont-Saint-Guibert, Belgium, – December 13th, 2024 BrightPath Bio (Tokyo Stock Exchange ...

December 13, 2024

Watch The Replay: From iPSCs to Functional NK Cell Therapy - A Client Journey

Watch The Replay: From iPSCs to Functional NK Cell Therapy - A Client Journey

October 24, 2024

Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditions

Development and characterization of iPSC-derived regulatory T cells – Towards an allogenic cell therapy for the treatment of autoimmunity and inflammatory conditions

December 3, 2024

Cellistic Announces Successful Certification of its GMP Facility Dedicated to iPSC-based Cell Therapies

Cellistic Announces Successful Certification of its GMP Facility Dedicated to iPSC-based Cell Therapies

November 21, 2024